AQST - Aquestive Therapeutics, Inc.
| Previous Close | 17.00 |
| Open | 17.30 |
| Bid | 16.57 x 900 |
| Ask | 21.00 x 800 |
| Day's Range | 16.57 - 17.54 |
| 52 Week Range | 13.61 - 20.70 |
| Volume | 23,156 |
| Avg. Volume | 123,240 |
| Market Cap | 414.789M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.76 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.75 |
- Associated Press•6 days ago
Aquestive Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the Warren, New Jersey-based company said it had a loss of 64 cents. Losses, adjusted for non-recurring costs, came to 49 cents per share. The specialty pharmaceutical company posted ...
- PR Newswire•6 days ago
Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
- Completed adult epilepsy monitoring study demonstrating that Libervant™ provides comparable bioavailability - Received FDA approval for SYMAPAZAN™ for the adjunctive treatment of seizures associated ...
- PR Newswire•11 days ago
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film
- SYMPAZAN is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ...
- PR Newswire•14 days ago
Aquestive Therapeutics to Present at the Stifel 2018 Healthcare Conference
WARREN, N.J. , Oct. 30, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products ...
- PR Newswire•18 days ago
Aquestive Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Business Highlights on November 6, 2018
WARREN, N.J. , Oct. 25, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products ...
- PR Newswire•19 days ago
Aquestive Therapeutics Announces Completion of Diazepam Buccal Film Adult Epilepsy Monitoring Unit (EMU) Clinical Study with Positive Topline Results
WARREN, N.J., Oct. 25, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company, today announced the completion of a pharmacokinetic epilepsy monitoring unit (EMU) study demonstrating that its investigational diazepam buccal film (DBF), tentatively named LibervantTM, provides comparable bioavailability whether administered between seizures (interictal) or during and shortly after seizures (ictal/peri-ictal) in adult patients with poorly controlled tonic-clonic seizures or focal seizures with impaired awareness. DBF, a novel formulation of diazepam as a small, thin film strip placed inside the cheek, is under development for the management of selected patients with refractory epilepsy who require intermittent use of diazepam to control episodes of increased seizure activity.
- PR Newswire•2 months ago
Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel
WARREN, N.J., Sept. 11, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced that Lori J. Braender, Esq. "We are pleased to welcome Lori," said Keith J. Kendall, Chief Executive Officer of Aquestive Therapeutics. Braender joins Aquestive from a 35-year career at Day Pitney LLP, where she was most recently Chair of the Life Sciences Practice Group.
- PR Newswire•2 months ago
Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™
WARREN, N.J. , Sept. 4, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products ...
- PR Newswire•2 months ago
Aquestive Therapeutics Announces Tentative FDA Approval for Sympazan™ (clobazam) Oral Film
WARREN, N.J., Aug. 31, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST) today announced that Sympazan™ (clobazam) oral film has received tentative approval by the U.S. Food and Drug Administration (FDA), for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.
- PR Newswire•3 months ago
Aquestive Therapeutics Announces Closing of Exercise of Underwriters' Over-Allotment Option in Initial Public Offering
WARREN, N.J. , Aug. 15, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products ...
- PR Newswire•3 months ago
Aquestive Therapeutics Names Sandy Costa as Chairman of the Board of Directors
WARREN, N.J., Aug. 13, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced that the Company's Board of Directors confirmed its plan to appoint Santo "Sandy" Costa as Chairman, effective as of August 8th. Mr. Costa joined Aquestive's Board in 2015 bringing over 40 years of experience in the pharmaceutical, healthcare and life sciences industries, as well as leadership in the legal sector. Douglas Bratton, Chairman since 2004, will continue to serve as a member of the Board of Directors.
- PR Newswire•3 months ago
Aquestive Therapeutics to Present at the 2018 Wedbush Healthcare Conference
WARREN, N.J. , July 31, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products ...
- PR Newswire•4 months ago
Aquestive Therapeutics Announces Closing of Initial Public Offering
WARREN, N.J. , July 27, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet ...
- PR Newswire•4 months ago
Aquestive Therapeutics Announces Pricing of Initial Public Offering
WARREN, N.J. , July 24, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet ...